Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
Importance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-06-01
|
Series: | Substance Abuse: Research and Treatment |
Online Access: | https://doi.org/10.1177/1178221817699247 |
id |
doaj-beaf43b7e28a42b3b2ea025dc5977e38 |
---|---|
record_format |
Article |
spelling |
doaj-beaf43b7e28a42b3b2ea025dc5977e382021-04-02T12:01:09ZengSAGE PublishingSubstance Abuse: Research and Treatment1178-22182017-06-011110.1177/1178221817699247Access to and Payment for Office-Based Buprenorphine Treatment in OhioTheodore V Parran0Joseph Z Muller1Elina Chernyak2Chris Adelman3Christina M Delos Reyes4Douglas Rowland5Mykola Kolganov6University Hospitals Case Medical Center, Cleveland, OH, USASchool of Medicine, Case Western Reserve University, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAUniversity Hospitals Case Medical Center, Cleveland, OH, USASchool of Medicine, Case Western Reserve University, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAImportance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. Design/Setting/Participants: Cross-sectional telephone survey of Drug Addiction Treatment Act–waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). Main Outcomes: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT. Results: Of the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio’s 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty Conclusions and Relevance: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion.https://doi.org/10.1177/1178221817699247 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Theodore V Parran Joseph Z Muller Elina Chernyak Chris Adelman Christina M Delos Reyes Douglas Rowland Mykola Kolganov |
spellingShingle |
Theodore V Parran Joseph Z Muller Elina Chernyak Chris Adelman Christina M Delos Reyes Douglas Rowland Mykola Kolganov Access to and Payment for Office-Based Buprenorphine Treatment in Ohio Substance Abuse: Research and Treatment |
author_facet |
Theodore V Parran Joseph Z Muller Elina Chernyak Chris Adelman Christina M Delos Reyes Douglas Rowland Mykola Kolganov |
author_sort |
Theodore V Parran |
title |
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio |
title_short |
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio |
title_full |
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio |
title_fullStr |
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio |
title_full_unstemmed |
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio |
title_sort |
access to and payment for office-based buprenorphine treatment in ohio |
publisher |
SAGE Publishing |
series |
Substance Abuse: Research and Treatment |
issn |
1178-2218 |
publishDate |
2017-06-01 |
description |
Importance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. Design/Setting/Participants: Cross-sectional telephone survey of Drug Addiction Treatment Act–waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). Main Outcomes: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT. Results: Of the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio’s 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty Conclusions and Relevance: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion. |
url |
https://doi.org/10.1177/1178221817699247 |
work_keys_str_mv |
AT theodorevparran accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT josephzmuller accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT elinachernyak accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT chrisadelman accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT christinamdelosreyes accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT douglasrowland accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio AT mykolakolganov accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio |
_version_ |
1721570422168748032 |